The popularity of Sildenafil initially fueled a boom for pharma, however recent developments present a complicated outlook for investors. Off-patent alternatives are reducing profits, and persistent litigation add more https://flynnuvma617493.suomiblog.com/the-blue-pill-and-big-pharma-a-volatile-bet-57006776